Novo Nordisk Rebrands to 'Novo' Amid Obesity Market Competition
Novo Nordisk is rebranding as 'Novo,' signaling a new chapter for the Danish pharmaceutical company amid growing competition in the obesity drug market. The firm announced corporate culture changes and strategic principles aimed at improving focus, speed, and performance while emphasizing patient-centric innovation and ethical standards. These moves come after Novo has lost significant ground to rival Eli Lilly, which now holds 60.9% of the U.S. weight loss medication market compared to Novo's 38.8%, according to IQVIA data cited by Lilly. Despite launching a successful oral version of Wegovy and surpassing three million prescriptions as of June, Novo has seen its stock fall about 15% this year amid investor concerns over delayed blockbuster products and the cancellation of trials for an experimental cardiovascular drug. The company plans to outline further strategic changes during its Capital Markets Day on September 21. The rebrand includes a new marketing campaign with the slogan 'Lasting Health Starts Now,' aiming to connect more directly with patients and stakeholders by promoting immediate progress toward long-term well-being.
Topics: corporate strategy market competition obesity drugs rebranding